Skip to main content

Research Repository

Advanced Search

Zinc-modified nanotransporter of doxorubicine for multi-targeted therapy of prostate cancer cells.

Skalickova, Sylvie; Loffelmann, Martin; Docekalova, Michaela; Uhlirova, Dagmar; Stankova, Martina; Kepinska, Marta; Milnerowicz, Halina; Fernandez, Carlos; Ruttkay-Nedecky, Branislav; Zidkova, Jarmila; Kizek, Rene


Sylvie Skalickova

Martin Loffelmann

Michaela Docekalova

Dagmar Uhlirova

Martina Stankova

Marta Kepinska

Halina Milnerowicz

Branislav Ruttkay-Nedecky

Jarmila Zidkova

Rene Kizek


Target therapy for oncologic diseases presents a big challenge for advance nanomedicine. In our work, we focused on multi-target approach development. Designed nanotransporter is based on polysaccharide chitosan which allows formation of nanoparticles. These nanoparticles can bind metal ions, mainly zinc (moreover, zinc stabilizes chitosan structure). The estimated zinc concentration was approximately 1 nmol/g of chitosan. In addition, chitosan nanoparticle (cage) irreversibly binds therapeutics which could be applied for targeted therapy of malignant tumours. Designed chitosan structure (LMQ, 10 g) encapsulation efficiency for doxorubicin was 50%. The pH change (tested interval 5 - 8) caused 20% release of doxorubicin from the nanocage. The nanotransporter is orientated to cancer tissue due the fact that the malignant cells highly express metallothionein (MT). The increased affinity of MT to zinc ions causes that the nanotransporter is preferentially bound to tumour regions with a high MT concentration. Our latest experimental results showed the changes in amino acid metabolism of prostate cancer signalized by increase in the amount of amino acid sarcosine. Therefore, the chitosan-based nanotransporter was modified by anti-sarcosine antibody. The functionality of designed nanotransporter was proved by ELISA with double detection of doxorubicin using fluorescence and by peroxidase activity of ABTS substrate. In another system, magnetic separation and identification of individual components of the nanotransporter were used. The sarcosine binding activity was estimated around 50%.


SKALICKOVA, S., LOFFELMANN, M., DOCEKALOVA, M., UHLIROVA, D., STANKOVA, M., KEPINSKA, M., MILNEROWICZ, H., FERNANDEZ, C., RUTTKAY-NEDECKY, B., ZIDKOVA, J. and KIZEK, R. 2017. Zinc-modified nanotransporter of doxorubicine for multi-targeted therapy of prostate cancer cells. In Proceedings of the 9th Nanomaterials international conference 2017 (NANOCON 2017): research and application, 18-20 October 2017, Brno, Czech Republic. Ostrava: Tanger Ltd [online], pages 531-536. Available from:

Conference Name 9th Nanomaterials international conference 2017 (NANOCON 2017): research and application
Conference Location Brno, Czech Republic
Start Date Oct 18, 2017
End Date Oct 20, 2017
Acceptance Date Oct 1, 2017
Online Publication Date Oct 20, 2017
Publication Date Mar 8, 2018
Publicly Available Date Dec 18, 2020
Publisher Tanger Ltd.
Pages 531-536
Series ISSN 2694-930X
ISBN 9788087294819
Keywords Antracycline antibiotics; Chitosan; Metallothionein; Nano medicine; Nanoparticles; Prostate cancer
Public URL
Publisher URL